全文获取类型
收费全文 | 5234篇 |
免费 | 357篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 131篇 |
儿科学 | 152篇 |
妇产科学 | 116篇 |
基础医学 | 755篇 |
口腔科学 | 172篇 |
临床医学 | 486篇 |
内科学 | 1041篇 |
皮肤病学 | 71篇 |
神经病学 | 298篇 |
特种医学 | 189篇 |
外国民族医学 | 3篇 |
外科学 | 876篇 |
综合类 | 99篇 |
一般理论 | 4篇 |
预防医学 | 295篇 |
眼科学 | 131篇 |
药学 | 420篇 |
中国医学 | 52篇 |
肿瘤学 | 329篇 |
出版年
2024年 | 5篇 |
2023年 | 56篇 |
2022年 | 135篇 |
2021年 | 230篇 |
2020年 | 145篇 |
2019年 | 192篇 |
2018年 | 248篇 |
2017年 | 149篇 |
2016年 | 168篇 |
2015年 | 186篇 |
2014年 | 261篇 |
2013年 | 300篇 |
2012年 | 531篇 |
2011年 | 471篇 |
2010年 | 237篇 |
2009年 | 190篇 |
2008年 | 274篇 |
2007年 | 278篇 |
2006年 | 252篇 |
2005年 | 211篇 |
2004年 | 173篇 |
2003年 | 172篇 |
2002年 | 150篇 |
2001年 | 55篇 |
2000年 | 57篇 |
1999年 | 52篇 |
1998年 | 41篇 |
1997年 | 28篇 |
1996年 | 27篇 |
1995年 | 15篇 |
1994年 | 25篇 |
1993年 | 20篇 |
1992年 | 30篇 |
1991年 | 24篇 |
1990年 | 21篇 |
1989年 | 18篇 |
1988年 | 24篇 |
1987年 | 28篇 |
1986年 | 9篇 |
1985年 | 17篇 |
1984年 | 8篇 |
1983年 | 6篇 |
1980年 | 7篇 |
1979年 | 10篇 |
1978年 | 9篇 |
1977年 | 5篇 |
1974年 | 11篇 |
1973年 | 10篇 |
1971年 | 8篇 |
1967年 | 4篇 |
排序方式: 共有5620条查询结果,搜索用时 15 毫秒
101.
Design,Synthesis, and Biological Evaluation of Thiazolidine‐2,4‐dione Conjugates as PPAR‐γ Agonists
下载免费PDF全文
![点击此处可从《Archiv der Pharmazie》网站下载免费的PDF全文](/ch/ext_images/free.gif)
102.
Khezri Mehrdad Shokoohi Mostafa Mirzazadeh Ali Tavakoli Fatemeh Ghalekhani Nima Mousavian Ghazal Mehmandoost Soheil Kazerooni Parvin Afsar Haghdoost Ali Akbar Karamouzian Mohammad Sharifi Hamid 《AIDS and behavior》2022,26(9):2831-2843
AIDS and Behavior - Injection drug use has been the leading route of HIV transmission in Iran. We assessed HIV prevalence, risk behaviors, and uptake of prevention services among people who inject... 相似文献
103.
Naga Venkata K. Pothineni MD Nigel Amankwah MD Pasquale Santangeli MD PhD Robert D. Schaller DO Gregory E. Supple MD Rajat Deo MD Saman Nazarian MD Fermin C. Garcia MD Sanjay Dixit MD David J. Callans MD Francis E. Marchlinski MD David S. Frankel MD 《Journal of cardiovascular electrophysiology》2021,32(2):345-353
104.
Amrish Deshmukh MD John Larson MD Michael Ghannam MD Mohammed Saeed MD Ryan Cunnane MD Hamid Ghanbari MD Rakesh Latchamsetty MD Thomas Crawford MD Krit Jongnarangsin MD Frank Pelosi Jr. MD Aman Chugh MD Hakan Oral MD Fred Morady MD Frank Bogun MD Jackson J. Liang DO 《Journal of cardiovascular electrophysiology》2021,32(12):3173-3178
105.
Ayman Saeyeldin Mohammad A. Zafar Lauren A. Baldassarre Hamid Mojibian Bulat A. Ziganshin Sandip K. Mukherjee John A. Elefteriades 《The International journal of angiology》2021,30(2):160
Aortic diameter is a powerful predictor of adverse aortic events, such as aortic rupture or dissection, forming the basis of prophylactic surgical repair criteria. Limited evidence is available regarding the association of aortic wall thickness (AWT) with these adverse aortic events. We present the case and surgical video of a 73-year-old man with chest pain and an increased AWT, who underwent ascending aortic repair and deep hemiarch placement under deep hypothermic circulatory arrest. Surgical pathology demonstrated evidence of aortic delamination and medial separation, indicative of an impending dissection. The patient recovered uneventfully, and his chest pain ultimately resolved after open repair. In this patient, increased AWT was felt to be the precursor to a potential aortic catastrophe. 相似文献
106.
AIMS: The aim of this study was to take a combination of animal and cell culture approaches to examine the individual responses of vascular cells to varying inflammatory factors in order to gain insights on the mechanism(s) by which poly(ADP-ribose) polymerase (PARP) inhibition promotes factors of plaque stability. METHODS AND RESULTS: Apolipoprotein (ApoE(-/-)) mice fed a high-fat diet were used as a model of atherosclerosis. Primary endothelial cells, smooth muscle cells (SMCs), and ex-vivo generated foam cells (FCs) were used in our in vitro studies. PARP inhibition significantly decreased the markers of oxidative stress and caspase-3 activation and increased smooth muscle actin within plaques from ApoE(-/-) mice fed a high-fat diet. PARP inhibition protected against apoptosis and/or necrosis in SMCs and endothelial cells in response to H(2)O(2) or tumour necrosis factor (TNF). Remarkably, PARP inhibition in FCs resulted in significant sensitization to 7-ketocholesterol (7-KC) by increasing cellular-toxic-free cholesterol, potentially through a down-regulation of acyl-CoA:cholesterol acyltransferase-1 (ACAT-1) expression. 7-KC induced necrosis exclusively in endothelial cells, which was, surprisingly, unaffected by PARP inhibition indicating that PARP inhibition does not prevent all forms of necrotic cell death. In SMCs, PARP-1 inhibition by gene deletion conferred protection against 7-KC or TNF, potentially by reducing caspase-3-like activation, preventing induction of c-Jun N-terminal protein kinase phosphorylation, and inducing extracellular signal-regulated kinase phosphorylation independently of PARP classical enzymatic activity. CONCLUSIONS: These data present PARP-1 as an important player in the death of cells constituting atherosclerotic plaques contributing to plaque dynamics. PARP inhibition may be a protective, a neutral, or a sensitizing factor. Additionally, PARP-1 may be a novel factor that can alter lipid metabolism. These novel functions of PARP not only challenge the current understanding of the role of the enzyme in cell death but also provide insights on the intricate contribution of PARP in cellular responses to predominant inflammatory factors within atherosclerotic plaques, presenting additional evidence for the viability of PARP inhibition as a therapeutic strategy for atherosclerosis. 相似文献
107.
108.
Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects 总被引:1,自引:0,他引:1
McClean DR Ikram H Mehta S Heywood JT Rousseau MF Niederman AL Sequeira RF Fleck E Singh SN Coutu B Hanrath P Komajda M Bryson CC Qian C Hanyok JJ;Omapatrilat Hemodynamic Study Group 《Journal of the American College of Cardiology》2002,39(12):2034-2041
OBJECTIVES: We investigated the acute and long-term hemodynamic and neurohumoral effects of the vasopeptidase inhibitor omapatrilat in human heart failure. BACKGROUND: Angiotensin-converting enzyme (ACE) inhibition constitutes a major advance in the treatment of chronic heart failure (CHF). Simultaneous inhibition of both neutral endopeptidase and ACE with omapatrilat may represent a new treatment strategy in CHF. METHODS: Three hundred and sixty-nine patients with symptomatic heart failure were randomized to double-blind treatment with omapatrilat (first 190 patients: 2.5 mg, 5 mg or 10 mg; last 179 patients: 2.5 mg, 20 mg or 40 mg once daily) for 12 weeks. RESULTS: Acutely, the 10 mg, 20 mg and 40 mg doses of omapatrilat produced greater reductions in pulmonary capillary wedge pressure (PCWP), systolic blood pressure (SBP) and systemic vascular resistance compared with 2.5 mg. Higher doses were associated with greater increases in vasodilator and natriuretic peptides, in addition to ACE inhibition. After 12 weeks, omapatrilat 20 mg and 40 mg showed greater falls from baseline in PCWP (40 mg: 0 h to 12 h average change -7.3 +/- 0.8 mm Hg) and SBP (40 mg: -11.7 +/- 1.7 mm Hg) than 2.5 mg (both p < 0.01 vs. 2.5 mg). The incidence of adverse experiences and patient withdrawal were similar in all groups. CONCLUSIONS: In CHF, the acute hemodynamic benefit seen with higher doses of omapatrilat was associated with increases in plasma vasodilator and natriuretic peptide levels in addition to ACE inhibition. After 12 weeks, the hemodynamic benefit was maintained. Omapatrilat may be a promising new agent in CHF. 相似文献
109.
Background : Viral kinetics suggests that daily administration of α‐interferon (IFN) will clear hepatitis C virus (HCV) RNA earlier and more frequently compared with standard t.i.w. To reduce the likelihood of viral replication, mutation and subsequent development of resistance, daily dosing with IFN may be appropriate. To determine the safety and efficacy of daily IFN with ribavirin in chronic HCV infection we performed a prospective study. Methods : Thirty‐five naïve adult HCV‐positive patients (25 male/10 female) were treated with IFN‐α2b; 5 MU daily for 2 weeks followed by 3 MU daily for 22 weeks and ribavirin 800–1200 mg/day depending on weight. Liver biopsy, performed in 25 patients, showed mild to moderate activity in 19 patients (76%) and severe activity in six patients (24%). Two patients showed staged IV fibrosis. Serotyping was performed in 29 patients by an enzyme immunoassay‐based Murex assay. Type 3 was the predominant serotype, present in 14 cases. Hepatitis C virus RNA was measured by the Chiron bDNA assay. Results : Mean baseline HCV‐RNA level was 14.2 ± 18.7 MEq/mL (median 6.09; range 0.2–92.5), which became undetectable in all but three patients at week 4. Normalization of alanine aminotransferase (ALT) at week 4 was seen in 27 patients. Three patients withdrew due to non‐compliance. Thirty‐two patients completed 24 weeks of therapy as per the protocol. At the end of treatment, the HCV‐RNA level was negative in 29 of 32 patients (90.6%) and ALT was normal in 31 of 32 patients (97%). Sustained viral response at 6 months follow up was seen in 28 of 32 patients (88%). The ALT level was normal in 28 of 32 patients (88%). Conclusion : Daily administration of IFN with ribavirin is well tolerated in the majority of patients. There is rapid elimination of virus with normalization of ALT and a significantly high sustained viral response. © 2002 Blackwell Publishing Asia Pty Ltd 相似文献
110.